s," including, without limitation, statements related to the continued listing of Cardica's common stock on The NASDAQ Global Market and potential outcomes following the appeal process. The word "will" and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause Cardica's results to differ materially from those indicated by these forward-looking statements, including, without limitation, the risk that the Panel may not overturn the staff's determination that Cardica has failed to meet the minimum continued listing requirements and the risk that Cardica otherwise fails to comply with the continued listing requirements of The NASDAQ Global Market or any other NASDAQ market, as well as other risks detailed from time to time in Cardica's SEC reports, including its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2009. Cardica expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. You are encouraged to read Cardica's reports filed with the U.S. Securities and Exchange Commission, available at www.sec.gov.
'/>"/>SOURCE Cardica, Inc. Copyright©2009 PR Newswire. All rights reserved | |
Page: 1 2 Related biology technology :1.
Cardicas C-Port(R) Flex A Anastomosis System Allows Surgeons to Perform Revolutionary Closed-Chest Heart Bypass Surgeries2.
Cardica Receives European CE Mark for C-Port Flex A System for Use in Coronary Artery Bypass Surgery3.
Cardica and Cook Sign Agreement to Expand Cook Vascular Closure Device Product Family4.
Cardica and Intuitive Surgical to Host Educational Symposium on Advanced Techniques and Technologies in Robotic Coronary Revascularization and Mitral Valve Repair5.
Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress6.
Cardica to Present at Jefferies 2nd Annual Healthcare Conference7.
Cardica Receives $1 Million Milestone Payment From Cook Medical for Development of Heart Defect Closure Device8.
Cardica Announces Fiscal 2009 First Quarter Financial Results9.
Cardica Announces Fiscal 2009 Second Quarter Financial Results10.
Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis11.
Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market